Aurora Kinase Inhibitors Based on the Imidazo[1,2-a]pyrazine Core: Fluorine and Deuterium Incorporation Improve Oral Absorption and Exposure
Journal of Medicinal Chemistry2010Vol. 54(1), pp. 201–210
Citations Over TimeTop 16% of 2010 papers
Angela D. Kerekes, Sara Esposite, Ronald J. Doll, Jayaram R. Tagat, Tao Yu, Yushi Xiao, Yonglian Zhang, D. B. Prelusky, Seema Tevar, Kimberly Gray, Gaby A. Terracina, Suining Lee, J. Shawn Jones, Ming Liu, Andrea Basso, Elizabeth B. Smith
Abstract
Aurora kinases are cell cycle regulated serine/threonine kinases that have been linked to cancer. Compound 1 was identified as a potent Aurora inhibitor but lacked oral bioavailability. Optimization of 1 led to the discovery of a series of fluoroamine and deuterated analogues, exemplified by compound 25, with an improved pharmacokinetic profile. We found that blocking oxidative metabolism at the benzylic position and decreasing the basicity of the amine are important to obtaining compounds with good biological profiles and oral bioavailability.
Related Papers
- → Aurora‐A Kinase: A Potent Oncogene and Target for Cancer Therapy(2016)300 cited
- → Clinical Experience with Aurora Kinase Inhibitors: A Review(2009)103 cited
- → Development and Biological Evaluation of a Novel Aurora A Kinase Inhibitor(2009)35 cited
- → Aurora A and B Kinases - Targets of Novel Anticancer Drugs(2010)16 cited
- Novel anti-tumor targets: aurora kinases and their small molecule inhibitors(2013)